Lipella Pharmaceuticals Inc. (LIPO)

Market Cap	2.31K -99.9%
Revenue (ttm)	389.78K -19.4%
Net Income	-5.33M
EPS	-1.76
Shares Out	4.62M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0005
Previous Close	0.0005
Day's Range	0.0005 - 0.0005
52-Week Range	0.0002 - 0.6407
Beta	1.58
Analysts	n/a
Price Target	n/a
Earnings Date	May 22, 2026

About Lipella Pharmaceuticals

Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It develops LP-10, a formulation of tacrolimus for patients with radiation-induced hemorrhagic cystitis; LP-310, a formulation of tacrolimus for the treatment of oral lichen planus; LP-410, an oral liposomal formulation of tacrolimus to treat oral graft-versus-host disease; and LP-50, an intravesical formulation of immunoglobul...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Employees: 7
• Stock Exchange: OTCMKTS
• Ticker Symbol: LIPO

Financial Performance

In 2024, Lipella Pharmaceuticals's revenue was $536,357, an increase of 19.29% compared to the previous year's $449,617. Losses were -$5.02 million, 8.60% more than in 2023.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Sep 8, 2026

Data Sources Report a data error